<PAGE>

                                                                   EXHIBIT 10.37

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED, OR REGISTERED OR QUALIFIED UNDER ANY
STATE SECURITIES OR "BLUE SKY" LAWS, AND MAY NOT BE SOLD, PLEDGED, OR OTHERWISE
TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT AND/OR LAWS
OR PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN
OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE CORPORATION AND ITS COUNSEL,
THAT SUCH REGISTRATION AND/OR QUALIFICATION IS NOT REQUIRED.

                            WARRANT TO PURCHASE STOCK

ISSUER: ATHENAHEALTH, INC., A DELAWARE CORPORATION
NUMBER OF SHARES: 5,000 SHARES, SUBJECT TO ADJUSTMENT
CLASS OF STOCK: SERIES E PREFERRED STOCK
EXERCISE PRICE: $5.04 PER SHARE, SUBJECT TO ADJUSTMENT
ISSUE DATE: NOVEMBER 8, 2006
EXPIRATION DATE: FEBRUARY 28, 2012

     THIS WARRANT CERTIFIES THAT, for the agreed upon value of $1.00 and for
other good and valuable consideration, BANC OF AMERICA STRATEGIC INVESTMENTS
CORPORATION, a Delaware corporation ("Holder") is entitled to purchase from
athenahealth, Inc., a Delaware corporation (the "Company"), up to 5,000 fully
paid and nonassessable shares (the "Shares") of the Company's Series E Preferred
Stock, at a purchase price per share of $5.04 (the "Exercise Price"). This
Warrant may be exercised in whole or in part at any time and from time to time
until 5:00 PM, Eastern time, on the Expiration Date and shall be void
thereafter. Until such time as this Warrant is exercised in full or expires, the
Exercise Price and the Shares are subject to adjustment as hereinafter provided.

ARTICLE 1. EXERCISE.

          1.1 Method of Exercise. Holder may exercise this Warrant by delivering
a duly executed Notice of Exercise in substantially the form attached as
Appendix 1 to the principal office of the Company. Unless Holder is exercising
the conversion right set forth in Section 1.2, Holder shall also deliver to the
Company a certified or bank check, or wire transfer to an account designated by
the Company, for the aggregate Exercise Price for the Shares being purchased.

          1.2 Conversion Right. In lieu of exercising this Warrant as specified
in Section 1.1, Holder may from time to time convert this Warrant, in whole or
in part, into a number of Shares (or Common Stock if the Series E Preferred
Stock has been automatically converted into Common Stock) determined by dividing
(a) the aggregate fair market value of the Shares (or other securities otherwise
issuable upon exercise of this Warrant) to be exercised minus the aggregate
Exercise Price of such Shares by (b) the fair market value of one Share (or


                                        1

<PAGE>

other such security). The fair market value of the Shares shall be determined
pursuant to Section 1.4.

          1.3 Intentionally Omitted.

          1.4 Fair Market Value. If the Shares are traded in a public market,
the fair market value of one Share shall be the closing price of such Share (or
the closing price of one share of the Company's stock into which the Shares are
convertible multiplied by the number of shares of such Company stock into which
each Share is then convertible) reported for the business day immediately before
Holder delivers its Notice of Exercise to the Company. If the Shares are not
traded in a public market, the Board of Directors of the Company shall determine
fair market value in its reasonable good faith judgment. The foregoing
notwithstanding, if Holder advises the Board of Directors in writing that Holder
disagrees with such determination, then the Company and Holder shall promptly
agree upon a reputable investment banking firm to undertake such valuation. If
the valuation of such investment banking firm is greater than that determined by
the Board of Directors by five percent (5%) or more, then all fees and expenses
of such investment banking firm shall be paid by the Company. In all other
circumstances, such fees and expenses shall be paid by Holder, but in all events
the determination of the investment banking firm as to fair market value shall
apply for purposes of Section 1.2 above.

          1.5 Delivery of Certificate and New Warrant. Promptly after Holder
exercises or converts this Warrant, the Company shall deliver to Holder
certificates for the Shares acquired and, if this Warrant has not been fully
exercised or converted and has not expired, a new Warrant representing the
Shares not so acquired.

          1.6 Replacement of Warrant. On receipt of evidence reasonably
satisfactory to the Company of the loss, theft, destruction or mutilation of
this Warrant and, in the case of loss, theft or destruction, on delivery of an
indemnity agreement reasonably satisfactory in form and amount to the Company
or, in the case of mutilation, on surrender and cancellation of this Warrant,
the Company at its expense shall execute and deliver, in lieu of this Warrant, a
new warrant of like tenor.

          1.7 Repurchase on Sale, Merger, or Consolidation of the Company.

               1.7.1. "Acquisition". For the purpose of this Warrant,
"Acquisition" means any sale, transfer, license, or other disposition of all or
substantially all of the assets of the Company, or any reorganization,
consolidation, or merger of the Company where the holders of the Company's
securities before the transaction beneficially own less than 50% of the
outstanding voting securities of the surviving entity after the transaction.

               1.7.2. Assumption of Warrant. Upon the closing of any Acquisition
the successor entity shall assume the obligations of this Warrant, and this
Warrant shall be exercisable for the same securities, cash, and property as
would be payable for the Shares issuable upon exercise of the unexercised
portion of this Warrant as if such Shares were outstanding on the record date
for the Acquisition and subsequent closing. The Exercise Price shall be adjusted
accordingly.


                                        2

<PAGE>

               1.7.3 Purchase Right. Notwithstanding the foregoing, at the
election of Holder, the Company shall purchase the unexercised portion of this
Warrant for cash upon the closing of any Acquisition in which the consideration
is solely cash or cash equivalents for an amount equal to (a) the fair market
value of any consideration that would have been received by Holder in
consideration of the Shares had Holder exercised the unexercised portion of this
Warrant immediately before the record date for determining the shareholders
entitled to participate in the proceeds of the Acquisition, less (b) the
aggregate Exercise Price of the Shares, but in no event less than zero.

          1.8 Automatic Exercise Prior to Expiration. To the extent this Warrant
is not previously exercised as to all of the Shares subject hereto, and if the
fair market value of one Share is greater than the Exercise Price then in
effect, this Warrant shall be deemed automatically exercised pursuant to Section
1.2 above (even if not surrendered) immediately before its expiration date as
set forth in this Warrant. For purposes of such automatic exercise, the fair
market value of one Share upon such expiration shall be determined pursuant to
Section 1.4 above. To the extent this Warrant or any portion thereof is deemed
automatically exercised pursuant to this Section, the Company agrees to promptly
notify the Holder of the number of Shares, if any, the Holder hereof is to
receive by reason of such automatic exercise.

ARTICLE 2. ADJUSTMENTS TO THE SHARES.

          2.1 Stock Dividends, Splits, Etc. If the Company declares or pays a
dividend on the outstanding shares of the same class or series as the Shares,
payable in Common Stock or other securities, or subdivides the outstanding
shares of the same class or series as the Shares into a greater amount of shares
of the same class or series as the Shares, or, if the Shares are securities
other than Common Stock, subdivides the Shares in a transaction that increases
the amount of Common Stock into which the Shares are convertible, then upon
exercise of this Warrant, for each Share acquired, Holder shall receive, without
cost to Holder, the total number and kind of securities to which Holder would
have been entitled had Holder owned the Shares of record as of the date the
dividend or subdivision occurred.

          2.2 Reclassification, Exchange or Substitution. Upon any
reclassification, exchange, substitution, or other event that results in a
change of the number and/or class of the Company's outstanding securities of the
same class or series as the Shares, Holder shall be entitled to receive, upon
exercise or conversion of this Warrant, the number and kind of securities and
property that Holder would have received for the Shares if this Warrant had been
exercised immediately before such reclassification, exchange, substitution, or
other event. Such an event shall include any automatic conversion of all (but
not less than all) of the outstanding securities of the Company of the same
class or series as the Shares to Common Stock pursuant to the terms of the
Company's Amended and Restated Certificate of Incorporation, as amended
(including without limitation any and all applicable Certificates of
Designation) ("Certificate of Incorporation") upon the closing of a registered
public offering of the Company's Common Stock. The Company or its successor
shall promptly issue to Holder a new Warrant for such new securities or other
property. The new Warrant shall provide for adjustments which shall be as


                                        3

<PAGE>

nearly equivalent as may be practicable to the adjustments provided for in this
Article 2 including, without limitation, adjustments to the Exercise Price and
to the number of securities or property issuable upon exercise of the new
Warrant. The provisions of this Section 2.2 shall similarly apply to successive
reclassifications, exchanges, substitutions, or other events.

          2.3 Adjustments for Combinations, Etc. If the outstanding shares of
the class or series of securities issuable upon exercise or conversion of this
Warrant are combined or consolidated, by reclassification or otherwise, into a
lesser number of shares, the Exercise Price shall be proportionately increased
and the number of Shares for which this Warrant is exercisable shall be
proportionately decreased.

          2.4 Adjustments for Dilutive Issuances. In the event of the issuance
(a "Dilutive Issuance") by the Company, after the Issue Date of the Warrant, of
securities of the same class or series as the Shares at a price per share less
than the Exercise Price, or securities which are convertible into or exercisable
or exchangeable for Common Stock at a Common Stock per share exercise or
conversion price or exchange rate that is less than the Exercise Price in effect
at such date, then the number of shares of Common Stock issuable upon conversion
of the Shares shall be adjusted in accordance with the provisions (the
"Provisions") of the Series E Preferred Stock of the Company as set forth in the
Certificate of Incorporation and in effect on the Issue Date of this Warrant.
The Company agrees that the Provisions shall not be restated, amended, modified
or waived in any manner such that the Holder hereof is treated differently than
other holders of the Series E Preferred Stock (as holders of Series E Preferred
Stock). Under no circumstances shall the aggregate Exercise Price payable by the
Holder upon exercise of the Warrant increase as a result of any adjustment
arising from a Dilutive Issuance.

          2.5 No Impairment. The Company shall not, by amendment of its
Certificate of Incorporation or the Provisions or through a reorganization,
transfer of assets, consolidation, merger, dissolution, issue, or sale of
securities or any other voluntary action, avoid or seek to avoid the observance
or performance of any of the terms to be observed or performed under this
Warrant by the Company, but shall at all times in good faith assist in carrying
out of all the provisions of this Article 2 and in taking all such action as may
be necessary or appropriate to protect Holder's rights under this Article
against impairment.

          2.6 Fractional Shares. No fractional Shares shall be issuable upon
exercise or conversion of the Warrant and the number of Shares to be issued
shall be rounded down to the nearest whole Share. If a fractional share interest
arises upon any exercise or conversion of the Warrant, the Company shall
eliminate such fractional share interest by paying Holder an amount computed by
multiplying the fractional interest by the fair market value of a full Share.

          2.7 Certificate as to Adjustments. Upon each adjustment as provided in
this Warrant of the number of Shares, the Exercise Price or the number of shares
of Common Stock into which the Shares are convertible, the Company at its
expense shall promptly compute such adjustment, and furnish Holder with a
certificate of its Chief Financial Officer setting forth such adjustment and the
facts upon which such adjustment is based. The Company shall, upon written
request, furnish Holder a certificate setting forth the number of Shares, the
Exercise Price and/or the ratio by which the Shares may be converted into shares
of Common Stock in effect upon the


                                        4

<PAGE>

date thereof and the series of adjustments leading to such number of Shares,
Exercise Price and/or ratio by which the Shares may be converted into shares of
Common Stock.

ARTICLE 3. REPRESENTATIONS AND COVENANTS OF THE COMPANY.

          3.1 Representations and Warranties. The Company hereby represents and
warrants to the Holder as follows:

               (a) All Shares which may be issued upon the exercise of this
Warrant, and all shares of Common Stock or other securities, if any, issuable
upon conversion of the Shares, shall, upon issuance, be duly authorized, validly
issued, fully paid and nonassessable, and free of any liens and encumbrances
except for restrictions on transfer provided for herein or under applicable
federal and state securities laws.

               (b) The authorized capital stock of the Company consists of the
following: 76,589,684 shares, consisting of 50,000,000 shares of common stock,
$.01 par value (the "Common Stock"), and 26,589,684 shares of Preferred Stock,
$.01 par value of which 1,600,000 shares have been designated Series A-l
Convertible Preferred Stock, 1,045,015 shares have been designated Series A-2
Convertible Preferred Stock, 1,250,000 shares have been designated Series B-l
Convertible Preferred Stock, 127,605 shares have been designated Series B-2
Convertible Preferred Stock, 8,000,000 shares have been designated Series C
Convertible Preferred Stock, 12,977,380 shares have been designated Series D
Preferred Stock, and 1,589,684 shares have been designated Series E Preferred
Stock. Schedule 3.1(b) sets forth all of the outstanding shares of Common Stock
and Preferred Stock and outstanding options, warrants, convertible securities,
convertible debentures, and rights to acquire, subscribe for, and/or purchase
any Common Stock, Preferred Stock and/or other capital stock of the Company or
any securities or debentures convertible into or exchangeable for Common Stock,
Preferred Stock and/or other capital stock of the Company.

               (c) The Exercise Price is equal to the lowest price per share of
Series E Preferred Stock issued by the Company.

               (d) The Conversion Price (as defined in the Provisions) per share
of the Series E Preferred Stock in effect on the Issue Date of this Warrant is
$5.04.

               (e) The Company covenants that it shall at all times cause to be
reserved and kept available out of its authorized and unissued shares such
number of shares of Series E Preferred Stock and shares of Common Stock and
other securities as will be sufficient to permit the exercise in full of this
Warrant and the conversion of the Shares into shares of Common Stock or such
other securities.

          3.2 Notice of Certain Events. If the Company proposes at any time (a)
to declare any dividend or distribution upon any of its capital stock, whether
in cash, property, stock, or other securities and whether or not a regular cash
dividend; (b) to offer for subscription pro rata to the holders of any class or
series of its stock any additional shares of stock of any class or series or
other rights; (c) to effect any reclassification or recapitalization of any of
its


                                        5

<PAGE>

securities; (d) to merge or consolidate with or into any other corporation, or
sell, lease, license, or convey all or substantially all of its assets, or to
liquidate, dissolve or wind up; or (e) offer holders of registration rights the
opportunity to participate in an underwritten public offering of the company's
securities for cash, then, in connection with each such event, the Company shall
give Holder (1) at least 20 days prior written notice of the date on which a
record will be taken for such dividend, distribution, or subscription rights
(and specifying the date on which the holders of securities of the Company) or
for determining rights to vote, if any, in respect of the matters referred to in
(c) and (d) above; (2) in the case of the matters referred to in (c) and (d)
above at least 20 days prior written notice of the date when the same will take
place (and specifying the date on which the holders of securities of the Company
will be entitled to exchange their securities of the Company for securities or
other property deliverable upon the occurrence of such event); and (3) in the
case of the matter referred to in (e) above, the same notice as is given to the
holders of such registration rights.

          3.3 Information Rights. So long as the Holder holds this Warrant
and/or any of the Shares, the Company shall deliver to the Holder (a) promptly
after mailing, copies of all notices or other written communications to the
shareholders of the Company, and (b) such financial reports as are generally
distributed to the holders of Series E Preferred Stock (or other securities
otherwise issuable upon exercise of this Warrant) of the Company concurrently
with the distribution thereof to such shareholders.

          3.4 Registration Under Securities Act of 1933, as amended. The shares
of Common Stock into which the Shares are convertible (or, if at any time the
Shares shall be shares of Common Stock, the Shares) shall have certain
registration rights pursuant to an Amendment No. 3 of even date herewith with
respect to that certain Registration Rights Agreement, dated as of September 9,
1999 (as amended), in effect between the Company and Holder. The Company
represents and warrants to Holder that the Company's execution, delivery and
performance of the aforesaid Amendment (a) has been duly authorized by all
necessary corporate action of the Company's Board of Directors and shareholders,
(b) will not violate the Company's Certificate of Incorporation or By-laws, each
as amended, (c) will not violate or cause a breach or default (or an event which
with the passage of time or the giving of notice or both, would constitute a
breach or default) under any agreement, instrument, mortgage, deed of trust or
other arrangement to which the Company is a party or by which it or any of its
assets is subject or bound, and (d) does not require the approval, consent or
waiver of or by any third party which approval, consent or waiver has not been
obtained as of the Issue Date of this Warrant.

ARTICLE 4. MISCELLANEOUS.

          4.1 Term; Notice of Expiration. Subject to Section 1.8 above, this
Warrant is exercisable, in whole or in part, at any time and from time to time
on or before the Expiration Date set forth above.

          4.2 Legends; Compliance with Securities Act. This Warrant and the
Shares (and the securities issuable, directly or indirectly, upon conversion of
the Shares, if any) shall be imprinted with a legend in substantially the
following form:


                                        6
<PAGE>

     THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
     AMENDED, OR REGISTERED OR QUALIFIED UNDER ANY STATE SECURITIES OR "BLUE
     SKY" LAWS, AND MAY NOT BE SOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT
     AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT AND/OR LAWS OR PURSUANT TO
     RULE 144 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF
     COUNSEL REASONABLY SATISFACTORY TO THE CORPORATION AND ITS COUNSEL, THAT
     SUCH REGISTRATION AND/OR QUALIFICATION IS NOT REQUIRED.

In addition, in connection with the issuance of this Warrant, the holder
specifically represents to the Company by acceptance of this Warrant as follows:

                    (a) The holder is aware of the Company's business affairs
and financial condition, and has acquired information about the Company
sufficient to reach an informed and knowledgeable decision to acquire this
Warrant. The holder is acquiring this Warrant for its own account for investment
purposes only and not with a view to, or for the resale in connection with, any
"distribution" thereof in violation of the Securities Act of 1933, as amended
(the "Act").

                    (b) The holder understands that this Warrant has not been
registered under the Act in reliance upon a specific exemption therefrom, which
exemption depends upon, among other things, the bona fide nature of the holder's
investment intent as expressed herein.

                    (c) The holder further understands that this Warrant must be
held indefinitely unless subsequently registered under the Act and qualified
under any applicable state securities laws, or unless exemptions from
registration and qualification are otherwise available. The holder is aware of
the provisions of Rule 144, promulgated under the Act.

                    (d) The holder is an "accredited investor" as such term is
defined in Rule 501 of Regulation D promulgated under the Act.

          4.3 Compliance with Securities Laws on Transfer. This Warrant and the
Shares issuable upon exercise of this Warrant (and the securities issuable,
directly or indirectly, upon conversion of the Shares, if any) may not be
transferred or assigned in whole or in part without compliance with applicable
federal and state securities laws by the transferor and the transferee
(including, without limitation, the delivery of investment representation
letters and legal opinions reasonably satisfactory to the Company, as reasonably
requested by the Company). The Company shall not require Holder to provide an
opinion of counsel if the transfer is to an affiliate of Holder or if there is
no material question as to the availability of current information as referenced
in Rule 144(c), Holder represents that it has complied with Rule 144(d) and (e)
in reasonable detail, the selling broker represents that it has complied with
Rule 144(f), and the Company is provided with a copy of Holder's notice of
proposed sale.


                                        7

<PAGE>

          4.4 Transfer Procedure. Subject to the provisions of Section 4.3
Holder may transfer all or part of this Warrant and/or the Shares issuable upon
exercise of this Warrant (or the securities issuable, directly or indirectly,
upon conversion of the Shares, if any) at any time to Silicon Valley Bancshares
or The Silicon Valley Bank Foundation, or, to any other transferee by giving the
Company notice of the portion of the Warrant being transferred setting forth the
name, address and taxpayer identification number of the transferee and
surrendering this Warrant to the Company for reissuance to the transferee(s)
(and Holder if applicable).

          4.5 Notices. All notices and other communications from the Company to
the Holder, or vice versa, shall be deemed delivered and effective when given
personally or sent by express overnight courier service, or mailed by
first-class registered or certified mail, postage prepaid, or by electronic
facsimile transmission with prompt confirmation by one of the foregoing means,
at such address as may have been furnished to the Company or the Holder, as the
case may be, in writing by the Company or such holder from time to time, but in
all cases, unless instructed in writing otherwise, the Company shall deliver a
copy of all notices to Holder to BANC OF AMERICA STRATEGIC INVESTMENTS
CORPORATION, 600 Montgomery Street, San Francisco, CA 94111, ATTN: Gary M.
Tsuyuki.

          4.6 Waiver. This Warrant and any term hereof may be changed, waived,
discharged or terminated only by an instrument in writing signed by the party
against which enforcement of such change, waiver, discharge or termination is
sought.

          4.7 Issue Tax. The issuance of the securities subject to this Warrant
shall be made without charge to the Holder for any issue tax (other than
applicable income taxes) in respect thereof.

          4.8 Attorneys Fees. In the event of any dispute between the parties
concerning the terms and provisions of this Warrant, the party prevailing in
such dispute shall be entitled to collect from the other party all costs
incurred in such dispute, including reasonable attorneys' fees.

          4.9 Governing Law. This Warrant shall be governed by and construed in
accordance with the laws of The Commonwealth of Massachusetts, without giving
effect to its principles regarding conflicts of law.

[remainder of page intentionally left blank; signature page immediately follows]


                                        8

<PAGE>

     IN WITNESS WHEREOF, the Company has caused this Warrant to be executed as
an instrument under seal by its duly authorized representative as of the date
first above written.

                                        ATHENAHEALTH, INC.


                                        By /s/ Carl Byers
                                           -------------------------------------
                                        Name Carl Byers
                                        Title Treasurer & CFO


                                        9

<PAGE>

                                   APPENDIX 1

                               NOTICE OF EXERCISE

          1. The undersigned hereby elects to purchase ________________ shares
of the ___________________ stock of athenahealth, Inc. pursuant to Section 1.1
of the attached Warrant, and tenders herewith payment of the purchase price of
such shares in full.

          1. The undersigned hereby elects to convert the attached Warrant into
Shares in the manner specified in Section 1.2 of the attached Warrant. This
conversion is exercised with respect to __________________ of shares of the
____________________________________ Stock of Athenahealth, Inc.

     [Strike paragraph that does not apply.]

     2. Please issue a certificate or certificates representing said shares in
the name of the undersigned or in such other name as is specified below:

               ______________________________________
               (Name)

               ______________________________________

               ______________________________________
               (Address)

     3. The undersigned represents it is acquiring the shares solely for its own
account and not as a nominee for any other party and not with a view toward the
resale or distribution thereof except in compliance with applicable securities
laws.


                                        ----------------------------------------
                                        (Signature)
------------------------------------
(Date)

                                   Appendix I

<PAGE>

                       Schedule 3.1 (b) -- Capitalization

Outstanding Capital Stock:

<TABLE>
<S>                                      <C>
Common Stock                             4,792,071 shares
Series A-l Convertible Preferred Stock   1,600,000 shares
Series A-2 Convertible Preferred Stock     787,748 shares
Series B-l Convertible Preferred Stock     627,000 shares
Series B-2 Convertible Preferred Stock      19,395 shares
Series C Convertible Preferred Stock     7,214,288 shares
Series D Convertible Preferred Stock     9,993,342 shares
Series E Convertible Preferred Stock     1,289,684 shares
</TABLE>

Outstanding options, warrants, convertible securities, convertible debentures,
and rights to acquire, subscribe for, and/or purchase any Common Stock and/or
other capital stock of the Company or any securities or debentures convertible
into or exchangeable for Common Stock and/or other capital stock of the Company:

<TABLE>
<S>                      <C>
Options                  2,839,667 shares of Common Stock
Warrants                    75,000 shares of Common Stock
                            31,481 shares of Series A-2 Preferred Stock
                            28,571 shares of Series C Preferred Stock
                           300,360 shares of Series D Preferred Stock
                           192,079 shares of Series E Preferred Stock

Convertible Debentures   none
Rights                   none
</TABLE>

                                Schedule 3.1 (b)